NMPA Approves PARP Inhibitor Pamiparib of BeiGene

NMPA Approves PARP Inhibitor Pamiparib of BeiGene

China’s regulatory body, the National Medical Products Administration (NMPA), has granted conditional approval to BeiGene’s PARP inhibitor pamiparib for treatment of patients advanced ovarian cancer. The approval marks the first for pamiparib and the third...